Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment

Clinica Terapeutica

Volumn 159, Issue 6, 2008, Pages 453-456

  Vici, P ^a   Viola, G ^a   Rossi, S ^b   Botti, C ^a   Vitucci, C ^a   Sergi, D ^a   Ferranti, F R ^a   Saracca, E ^a   Di Lauro, L ^a   Corsetti, S ^a   Foggi, P ^a   Fattoruso, S I S ^a   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Dipartimento Medico Sanofi Aventis   (Italy)

Author keywords

Adjuvant treatment; Anthracyclines; Sequence; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS-OVER STUDIES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; PACLITAXEL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 58849133796     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Early Breast Cancer Trialist's Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717
2. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93:293-301
3. De Laurentis M, Cancello G, D'Agostino D, et al. Taxane- based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26:44-53
4. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83
5. Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007; CD004421
6. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel spirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24:5664-71
7. Martin M, Lluch A, Segui MA, et al. Toxicity and health- related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte.colony stimulating factor to the TAC regimen. Ann Oncol 2006; 1'7(8):1205-12
8. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46:3876-85
9. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-69
10. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. J Clin Oncol 2004; 22:2587-93
11. Khayat D, Chollet P, Antoine EC, et al. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophsphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2001;19:3367-75
12. Deutsch M, Lambert-Falls R, Desch C, et al. Epirubicin combined with docetaxel or paclitaxel for node positive breast cancer, an exploratory analysis from a phase III study. Breast Cancer Res Treat 2006; 2103
13. Francis P, Brown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008; 100:121-33
14. Bumell MJ. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA. 21). Proc Am Soc Clin Oncol 2007; 25:550
15. Ellis PA, Barrett-Lee PJ, Bloomfield D, et al. Preliminary results of the UK taxotere as adjuvant chemotherapy (TACT) trial. Breast Cancer Res Treat 2007; 106:78
16. Eierman W, Pienkowsky T, Crown J, et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophoshpamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in HER2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005; 1069
17. Perez EA, Geeraerts L, Suman VJ, et al. A randomized phase II study of sequential docetaxel and doxorubicine/cyclophos- phamide in patients with metastatic breast cancer. Ann Oncol 2002; 13:1225-35
18. Spielmann M, Tubiana-Hulin M, Namer M, et al. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: A randomized phase II trial. Br J Cancer 2002; 86:692-7
19. Paridaens R, Van Aelst F, Georgoulias V, et al. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol 2003; 14:433-40
20. Cresta S, Grassel G, Mansutti M, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004; 15:433-9
21. Anton A, Hornedo J, Lluch A et al. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 2003; 4:286-91
22. Ramaswamy N, Povoski SP, Rhoades C, et al. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 2005; 93:97-74
23. Vici P, Foggi P, Colucci G, et al. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced in advanced breast cancer. Anticancer Res 2005; 25:1309-14
24. Piedbois P, Serin D, Priou F, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EOT), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks: AERO B03 randomized phase II study. Ann Oncol 2007; 18:52-7
25. Puhalla S, Mrozek E, Young D et al. Randomized phase II adjuvant trial of dose-sense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 2008;26:1691-7
26. Miller KD, Soule SE, Calley C, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel: Primary chemotherapy as biomarkers discovery laboratory. Breast Cancer Res Treat 2005; 89:187-97
27. Wildiers H, Dirix L, Neven P, et al. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 2008; 16
28. Lopez M. Toxicity of epirubicin and cyclophosphamide (EC) vs. docetaxel (D) followed by EC in the adjuvant (adj) treatment of node positive breast cancer. A multicenter randomized phase III study (GOIM9902). Proc Am Soc Clin Oncol 2006; 24:10526
29. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18:724-33
30. Guo B, Villeneuve DJ, Hembruff SL, et al. Bross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004; 85:31-51